SkinBioTherapeutics plc

Equities

SBTX

GB00BF33H870

Biotechnology & Medical Research

Market Closed - London S.E. 11:35:11 2024-04-26 am EDT 5-day change 1st Jan Change
9.25 GBX 0.00% Intraday chart for SkinBioTherapeutics plc 0.00% -39.34%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
SkinBioTherapeutics Gets Bond Conversion Notice from Macquarie MT
SkinBioTherapeutics half-year revenue jumps on UK-based sales AN
SkinBioTherapeutics plc Provides Earnings Guidance for the Year Ending June 30, 2024 CI
SkinBioTherapeutics plc Reports Earnings Results for the Half Year Ended December 31, 2023 CI
SkinBioTherapeutics' Chief Scientific Officer to Step Down MT
SkinBioTherapeutics Launches Project for Development of Wound Healing Technology MT
SkinBioTherapeutics announces research into wound healing bacterium AN
Cath O'Neill Confirms Intention to Stand Down as Chief Scientific Officer and Move to a Scientific Adviser Role at SkinBioTherapeutics plc CI
SkinBioTherapeutics plc Initiates a Research and Development Project with the University of Manchester CI
SkinBioTherapeutics Gets Bond Conversion Notice From Macquarie MT
Avacta plans fundraise to fund clinical development AN
Windward extends LSEG pact; Vinanz eyes DTC trading AN
SkinBioTherapeutics Reports ‘Very Positive’ Interim Data from Acne Food Supplement Study MT
SkinBioTherapeutics plc Announces Positive Interim Data from Consumer Participant Study for Acne CI
SkinBio's Dermatonics launches Once Heel Balm in Asia, ME and Africa AN
SkinBioTherapeutics Unit Plans Roll Out of Dry Foot Skin Treatment Balm MT
SkinBioTherapeutics up after successful year for Dermatonics AN
SkinBioTherapeutics completes Dermatonics purchase AN
SkinBioTherapeutics Finalizes Dermatonics Purchase; Shares Fall MT
SkinBioTherapeutics plc acquired Dermatonics Ltd. CI
SkinBioTherapeutics buys Dermatonics; in talks for 2nd deal AN
SkinBioTherapeutics Obtains GBP5 Million Convertible Bond Loan MT
SkinBioTherapeutics to Buy Skin Cream Brand Dermatonics MT
SkinBioTherapeutics plc agreed to acquire Dermatonics Ltd for £1.68 million. CI
SkinBioTherapeutics suffers acquisition delay but aims for early 2024 AN
Chart SkinBioTherapeutics plc
More charts
SkinBioTherapeutics plc is a United Kingdom-based life science company, which is focused on skin health. The principal activity of the Company is that of research and development focused on harnessing the microbiome for human health. The Company’s segments include UK, US, and EU. The Company's platform technology, SkinBiotix, applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company is targeting five specific skin healthcare sectors, such as cosmetics skincare, food supplements for the treatment of skin conditions, medical skin care, infection control in both the home and the hospital environment, and pharmaceuticals for the prescribed treatment of skin conditions. The Company's product, AxisBiotix-Ps, is a food supplement to address the symptoms of mild to moderate psoriasis. The Company is also focused on the application of SkinBiotix technology in the treatment of various classes of skin wounds.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. SBTX Stock
  4. News SkinBioTherapeutics plc
  5. SkinBioTherapeutics Unit Plans Roll Out of Dry Foot Skin Treatment Balm